Fibrinogen and fibrin clot structure in diabetes

被引:12
作者
Dunn, EJ [1 ]
Ariëns, RAS [1 ]
机构
[1] Univ Leeds, Sch Med, Acad Unit Mol Vasc Med, Leeds LS2 9JT, W Yorkshire, England
基金
英国医学研究理事会; 英国惠康基金;
关键词
fibrinogen; diabetes; glycation; clot; lysis;
D O I
10.1007/s00059-004-2607-z
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Diabetes is associated with an increased risk of developing cardiovascular disease, which is not fully accounted for by the accumulation of classic cardiovascular risk factors in patients. Recent evidence has demonstrated fibrinogen to be a powerful independent risk marker for cardiovascular disease in the general population, and it is also likely to contribute toward the increased atherosclerotic risk in diabetes. The etiology of hyperfibrinogenemia in diabetes is likely to be multifactorial, and at present the mechanisms involved have not been clarified. However, insulin, insulin resistance and inflammation are likely to be involved, especially in type 2 diabetes. The influence of diabetes in determining an individual's atherothrombotic risk is likely to extend beyond that of elevated fibrinogen levels, and may also act via changes in the structure and function of the fibrin clot that forms. Further research is needed to determine the mechanisms underlying these changes, which may lead to development of future interventions to reduce the excessive vascular risk associated with this disease.
引用
收藏
页码:470 / 479
页数:10
相关论文
共 118 条
[1]  
[Anonymous], 1995, Diabetes in America
[2]   The factor XIII V34L polymorphism accelerates thrombin activation of factor XIII and affects cross-linked fibrin structure [J].
Ariens, RAS ;
Philippou, H ;
Nagaswami, C ;
Weisel, JW ;
Lane, DA ;
Grant, PJ .
BLOOD, 2000, 96 (03) :988-995
[3]   Elevation of fibrinogen and thrombin-antithrombin III complex levels of type 2 diabetes mellitus patients with retinopathy and nephropathy [J].
Asakawa, H ;
Tokunaga, K ;
Kawakami, F .
JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2000, 14 (03) :121-126
[4]  
Avellone G, 1994, Diabetes Res, V25, P85
[5]   DECREASED PLASMINOGEN-ACTIVATOR INHIBITOR-1 ACTIVITY IN NEWLY-DIAGNOSED TYPE-2 DIABETIC-PATIENTS FOLLOWING DIETARY MODIFICATION [J].
BAHRU, Y ;
KESTEVEN, P ;
ALBERTI, KGMM ;
WALKER, M .
DIABETIC MEDICINE, 1993, 10 (09) :802-806
[6]   Insulin acutely increases fibrinogen production in individuals with type 2 diabetes but not in individuals without diabetes [J].
Barazzoni, R ;
Kiwanuka, E ;
Zanetti, M ;
Cristini, M ;
Vettore, M ;
Tessari, P .
DIABETES, 2003, 52 (07) :1851-1856
[7]   Increased fibrinogen production in type 2 diabetic patients without detectable vascular complications: Correlation with plasma glucagon concentrations [J].
Barazzoni, R ;
Zanetti, M ;
Davanzo, G ;
Kiwanuka, E ;
Carraro, P ;
Tiengo, A ;
Tessari, P .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2000, 85 (09) :3121-3125
[8]  
BAUMANN RE, 1993, THROMB HAEMOSTASIS, V69, P961
[9]  
Becker A, 2003, NETH J MED, V61, P129
[10]   NATIVE FIBRIN GEL NETWORKS OBSERVED BY 3D MICROSCOPY, PERMEATION AND TURBIDITY [J].
BLOMBACK, B ;
CARLSSON, K ;
HESSEL, B ;
LILJEBORG, A ;
PROCYK, R ;
ASLUND, N .
BIOCHIMICA ET BIOPHYSICA ACTA, 1989, 997 (1-2) :96-110